Targeted Therapy

Emerging Treatments for HER2-positive Early-stage Breast Cancer: Focus on Neratinib

Emerging Treatments for HER2-positive Early-stage Breast Cancer: Focus on Neratinib

[OncoTargets and Therapy] This research reviews available data on the role of the HER2 pathway in breast cancer and on the different targeted agents for the treatment of patients with early-stage HER2-positive disease, with a particular focus on neratinib.

A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer

A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer

By

CDK4/6 inhibitors, which block the activity of regulatory enzymes, are tolerated fairly well in patients with cancer; however, oncology nurses should be aware of some strategies that minimize their adverse effects.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

By

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

By

A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

By

Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Spherical Shape of New Drug Holds Promise for Bypassing the Blood Brain Barrier and Treating Aggressive Brain Cancer

Spherical Shape of New Drug Holds Promise for Bypassing the Blood Brain Barrier and Treating Aggressive Brain Cancer

By

An investigational drug with a novel spherical nucleic acid structure has the potential to cross the blood-brain barrier to treat glioblastoma multiforme.

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

By

A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.

PAD4 Inhibition Repairs, Reverses Cancer Tumor-Induced Kidney Damage

PAD4 Inhibition Repairs, Reverses Cancer Tumor-Induced Kidney Damage

By

A potential treatment targeting neutrophils holds promise for limiting kidney damage and improving renal function in cancer.

Outcomes Improved When Targeted Cancer Therapies Based on Multigene Panel

Outcomes Improved When Targeted Cancer Therapies Based on Multigene Panel

By

Progression-free survival rates are higher in patients treated with targeted therapies based on results of multigene panel tests.

Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options

Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options

By

Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

By

Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.

GARD: A Move Toward Precision Radiation Therapy

GARD: A Move Toward Precision Radiation Therapy

By

A new tool may enable oncologists to deliver radiation therapy targeted to a tumor's biology and radiosensitivity, similar to how anticancer agents target specific tumor mutation-affected gene pathways.

New Targeted Therapy with a Double-Pronged Approach

New Targeted Therapy with a Double-Pronged Approach

By

A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

By

Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.

Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer

Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer

By

Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.

Rare Mutations in Immune-Related Genes Linked to Multiple Simultaneous Colorectal Cancer Tumors

By

Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.

Surgery Improves Survival in Metastatic Kidney Cancer, But Is Little Used

By

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.

Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer

Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer

By

Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

By

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer

By

A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.

Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments

Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments

By

Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.

Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia

By

The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

By

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

By

The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

By

The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

By

Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

By

Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs